CHD vs RCUS

For growth investors, Church & Dwight Co.

, Inc. (CHD) is the stronger pick with 1. 6% revenue growth year-over-year, versus -4. 3% for Arcus Biosciences, Inc. (RCUS). Church & Dwight Co. , Inc. (CHD) offers the better valuation at 31. 0x trailing P/E (24. 9x forward), making it the more compelling value choice. Analysts rate Church & Dwight Co. , Inc. (CHD) a "Buy" — based on 34 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Church & Dwight Co.

, Inc. (CHD) delivered a total return of +12. 2%, compared to -15. 8% for Arcus Biosciences, Inc. (RCUS). Over 10 years, the gap is even starker: CHD returned +117. 3% versus RCUS's +53. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Church & Dwight Co.

, Inc. (CHD) is the lower-risk stock at 0. 14β versus Arcus Biosciences, Inc. 's 1. 95β — meaning RCUS is approximately 1304% more volatile than CHD relative to the S&P 500. On balance sheet safety, Arcus Biosciences, Inc. (RCUS) carries a lower debt/equity ratio of 16% versus 55% for Church & Dwight Co. , Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Church & Dwight Co.

, Inc. (CHD) is pulling ahead at 1. 6% versus -4. 3% for Arcus Biosciences, Inc. (RCUS). On earnings-per-share growth, the picture is similar: Church & Dwight Co. , Inc. grew EPS 27. 4% year-over-year, compared to -4. 8% for Arcus Biosciences, Inc.. Over a 3-year CAGR, RCUS leads at 30. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Church & Dwight Co.

, Inc. (CHD) is the more profitable company, earning 11. 9% net margin versus -142. 9% for Arcus Biosciences, Inc. — meaning it keeps 11. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CHD leads at 17. 4% versus -156. 3% for RCUS. At the gross margin level — before operating expenses — RCUS leads at 96. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RCUS: 15.

1% to $30. 00.

In this comparison, CHD (1.

3% yield) pays a dividend. RCUS does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Church & Dwight Co.

, Inc. (CHD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 1. 3% yield, +117. 3% 10Y return). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 95 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CHD: +117. 3%, RCUS: +53. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CHD (Consumer Defensive) and RCUS (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

CHD pays a dividend while RCUS does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.